They may have wanted to wait a little bit longer. This could go well below $3. The SP is at the mercy of the market and the uncertainty of the trials. Results are a long way off so we may as well get use to this as frustrating as it may be.
As insiders can not purchase within certain time frames from an event they are aware of, and several insiders have purchased there can be NO major announcement made that they are currently aware of. Thus no positive news for some time. May as well go fishing if you have the mind to.
"The SP is at the mercy of the market and the uncertainty of the trials. Results are a long way off so we may as well get use to this as frustrating as it may be."
- unfortunately for yourself and the other human garbage which pollutes this forum, Q1 2013 is by no means a long way off on an institutional time scale.
Imo what you almost certainly WILL have to get used to is the result of the share price being at the mercy of a market which sees the likelihood of clinical trial success as very high.
About the only likely value in your post is your prediction of frustration, caused by watching the share price driven to successively higher levels by the tutes looking to accumulate millions of shares before the end of this year.
Sharoky has little choice and that means nothing to an upstart like Insmed/Transave.This stock has a good chance of being cut in half in the next year or more.I have been short since early May.The amount of insider buys"is very small.